Share：
Share this content in WeChat
X
[Chinese][PDF]2833
• Clinical Article •
Diagnostic value of DCE-MRI texture analysis for molecular typing of breast cancer
LIN Qian  CHEN Aihua  ZHANG Tingting 

Cite this article as: LIN Q, CHEN A H, ZHANG T T. Diagnostic value of DCE-MRI texture analysis for molecular typing of breast cancer[J]. Chin J Magn Reson Imaging, 2023, 14(12): 40-48. DOI:10.12015/issn.1674-8034.2023.12.007.


[Abstract] Objective To explore the value of texture features based on dynamic contrast-enhanced MRI (DCE-MRI) images in preoperative prediction of molecular typing of breast cancer.Materials and Methods The preoperative MRI images and clinicopathological data of 75 patients with breast cancer confirmed by postoperative pathology in the First People's Hospital of Yichang from October 2021 to October 2022 were retrospectively analyzed. The general data of patients were analyzed by chi-square test and variance analysis. Feature parameters were extracted from DCE-MRI images for molecular subtypes with yes and no as binary classification indicators. Dimension reduction of feature parameters was performed by standardized and optimal feature filters. Independent sample t-test or Mann-Whitney U test was used to identify the optimal texture parameters with statistically significant differences between different groups. The area under the ROC curve (AUC) was used to evaluate the diagnostic efficacy of texture analysis. In addition, a logistic regression classification model was constructed based on dynamic enhanced MRI texture features, and the ROC curve was drawn to evaluate the diagnostic efficacy of the model for different molecular subtypes.Results There were 11 cases of Luminal A type, 36 cases of Luminal B type, 14 cases of human epidermal growth factor receptor 2 (HER-2) overexpression type and 14 cases of triple negative breast cancer (TNBC). There was no significant difference in age, menopausal status, pathological classification, MRI enhancement and lymph node status among patients with different subtypes of breast cancer (P＞0.05). The AUC [95% confidence interval (CI)] values of Luminal A, Luminal B, HER-2 overexpression and TNBC were 0.92 (0.77-1.00), 0.83 (0.62-1.00), 0.83 (0.55-1.00) and 0.72 (0.43-1.00), respectively. There were statistically significant differences in the three texture parameters between Luminal A and non-Luminal A groups (P＜0.05). The AUC values of the three were 0.73, 0.70 and 0.75, respectively. When the texture feature 3D grey level co-occurrence matrix cluster shadow (3D_glcm_CS)＞0.439, the diagnostic efficiency of Luminal A type was the highest. There were significant differences in the two texture features between Luminal B group and non-Luminal B group (P＜0.05). When original gray level co-occurrence matrix cluster shadow (o_glcm_CS)＞0.169, the diagnostic efficiency of Luminal B type was the best. There were statistically significant differences in the five texture features between the HER-2 overexpression group and the non-HER-2 overexpression group. The AUC values were 0.76, 0.81, 0.79, 0.80 and 0.82, respectively. When 3D grey level size zone matrix small area low gray level emphasis (3D_glszm_SALGLE)≤-0.460, the diagnostic efficiency of HER-2 overexpression was the highest (AUC=0.82, P＜0.001). Only the difference of texture feature wavelet LH neighbouring gray tone difference matrix busyness (w-LH_ngtdm_B) between TNBC and non-TNBC was statistically significant, and the AUC value was 0.65.Conclusions DCE-MRI texture analysis can noninvasively and effectively predict the molecular subtypes of breast cancer, which has important guiding value for the classification of preoperative molecular subtypes of breast cancer.
[Keywords] breast neoplasms；molecular typing；diagnostic value；texture analysis；dynamic contrast-enhanced；magnetic resonance imaging

LIN Qian   CHEN Aihua   ZHANG Tingting*  

Department of Radiology, the People's Hospital of China Three Gorges University (the First People's Hospital of Yichang), Yichang 443000, China

Corresponding author: ZHANG T T, E-mail: tiana0916@sina.com

Conflicts of interest   None.

ACKNOWLEDGMENTS Beijing Medical Award Foundation Ruiying Fund Project (No. YXJL-2022-0105-0133).
Received  2023-05-05
Accepted  2023-11-24
DOI: 10.12015/issn.1674-8034.2023.12.007
Cite this article as: LIN Q, CHEN A H, ZHANG T T. Diagnostic value of DCE-MRI texture analysis for molecular typing of breast cancer[J]. Chin J Magn Reson Imaging, 2023, 14(12): 40-48. DOI:10.12015/issn.1674-8034.2023.12.007.

[1]
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]
GIAQUINTO A N, SUNG H, MILLER K, et al. Breast cancer statistics, 2022[J]. CA: a cancer journal for clinicians, 2022, 72(6): 524-541. DOI: 10.3322/caac.21754.
[3]
LAMBIN P, RIOS-VELAZQUEZ E, LEIJENAAR R, et al. Radiomics: extracting more information from medical images using advanced feature analysis[J]. Eur J Cancer, 2012, 48(4): 441-446. DOI: 10.1016/j.ejca.2011.11.036.
[4]
ZHU B Y, CHEN H. Research on methods and application of texture analysis of medical images[J]. China Med Equip, 2013, 10(8): 77-81. DOI: 10.3969/J.ISSN.1672-8270.2013.08.028.
[5]
Breast Cancer Committee of Chinese Anticancer Association. Guidelines and norms for diagnosis and treatment of breast cancer of China Anti-Cancer Association (2021 edition)[J]. China Oncol, 2021, 31(10): 954-1040. DOI: 10.19401/j.cnki.1007-3639.2021.10.013.
[6]
BURSTEIN H J, CURIGLIANO G, THÜRLIMANN B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021[J]. Ann Oncol, 2021, 32(10): 1216-1235. DOI: 10.1016/j.annonc.2021.06.023.
[7]
SLOSTAD J A, YUN N K, SCHAD A E, et al. Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: a single institution experience[J]. Cancer Med, 2022, 11(24): 4954-4965. DOI: 10.1002/cam4.4843.
[8]
ZHAO Q F, XIE T W, FU C X, et al. Differentiation between idiopathic granulomatous mastitis and invasive breast carcinoma, both presenting with non-mass enhancement without rim-enhanced masses: the value of whole-lesion histogram and texture analysis using apparent diffusion coefficient[J/OL]. Eur J Radiol, 2020, 123: 108782 [2023-05-04]. https://pubmed.ncbi.nlm.nih.gov/31864142/. DOI: 10.1016/j.ejrad.2019.108782.
[9]
KAMIYA S, SATAKE H, HAYASHI Y, et al. Features from MRI texture analysis associated with survival outcomes in triple-negative breast cancer patients[J]. Breast Cancer, 2022, 29(1): 164-173. DOI: 10.1007/s12282-021-01294-1.
[10]
LU H C, YIN J D. Texture analysis of breast DCE-MRI based on intratumoral subregions for predicting HER2 2+ status[J/OL]. Front Oncol, 2020, 10: 543 [2023-05-04]. https://pubmed.ncbi.nlm.nih.gov/32373531/. DOI: 10.3389/fonc.2020.00543.
[11]
JIANG Z J, SONG L R, LU H C, et al. The potential use of DCE-MRI texture analysis to predict HER2 2+ status[J/OL]. Front Oncol, 2019, 9: 242 [2023-05-04]. https://pubmed.ncbi.nlm.nih.gov/31032222/. DOI: 10.3389/fonc.2019.00242.
[12]
CAO K, ZHAO B, LI X T, et al. Texture analysis of dynamic contrast-enhanced MRI in evaluating pathologic complete response (pCR) of mass-like breast cancer after neoadjuvant therapy[J/OL]. J Oncol, 2019, 2019: 4731532 [2023-05-04]. https://pubmed.ncbi.nlm.nih.gov/31949430/. DOI: 10.1155/2019/4731532.
[13]
HENDERSON S, PURDIE C, MICHIE C, et al. Interim heterogeneity changes measured using entropy texture features on T2-weighted MRI at 3.0T are associated with pathological response to neoadjuvant chemotherapy in primary breast cancer[J]. Eur Radiol, 2017, 27(11): 4602-4611. DOI: 10.1007/s00330-017-4850-8.
[14]
EUN N L, KANG D, SON E J, et al. Texture analysis using machine learning-based 3-T magnetic resonance imaging for predicting recurrence in breast cancer patients treated with neoadjuvant chemotherapy[J]. Eur Radiol, 2021, 31(9): 6916-6928. DOI: 10.1007/s00330-021-07816-x.
[15]
CHEN Y S, SUN S J, YU X J, et al. 3.0 T MRI features of breast cancer in different molecular types[J]. Chin J Magn Reson Imag, 2021, 12(2): 24-28. DOI: 10.12015/issn.1674-8034.2021.02.006.
[16]
COATES A S, WINER E P, GOLDHIRSCH A, et al. Tailoring therapies: improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015[J]. Ann Oncol, 2015, 26(8): 1533-1546. DOI: 10.1093/annonc/mdv221.
[17]
BRAMAN N, PRASANNA P, WHITNEY J, et al. Association of peritumoral radiomics with tumor biology and pathologic response to preoperative targeted therapy for HER2 (ERBB2)-positive breast cancer[J/OL]. JAMA Netw Open, 2019, 2(4): e192561 [2023-05-05]. https://pubmed.ncbi.nlm.nih.gov/31002322/. DOI: 10.1001/jamanetworkopen.2019.2561.
[18]
SUTTON E J, DASHEVSKY B Z, OH J H, et al. Breast cancer molecular subtype classifier that incorporates MRI features[J]. J Magn Reson Imaging, 2016, 44(1): 122-129. DOI: 10.1002/jmri.25119.
[19]
CANCER GENOME ATLAS NETWORK. Comprehensive molecular portraits of human breast tumours[J]. Nature, 2012, 490(7418): 61-70. DOI: 10.1038/nature11412.
[20]
ELLIS M J, DING L, SHEN D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition[J]. Nature, 2012, 486(7403): 353-360. DOI: 10.1038/nature11143.
[21]
PEROU C M, SØRLIE T, EISEN M B, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797): 747-752. DOI: 10.1038/35021093.
[22]
SUN X R, HE B, LUO X, et al. Preliminary study on molecular subtypes of breast cancer based on magnetic resonance imaging texture analysis[J]. J Comput Assist Tomogr, 2018, 42(4): 531-535. DOI: 10.1097/RCT.0000000000000738.
[23]
TSAI W C, CHANG K M, KAO K J. Dynamic contrast enhanced MRI and intravoxel incoherent motion to identify molecular subtypes of breast cancer with different vascular normalization gene expression[J]. Korean J Radiol, 2021, 22(7): 1021-1033. DOI: 10.3348/kjr.2020.0760.
[24]
HUANG J L, LIN Q, CUI C X, et al. Correlation between imaging features and molecular subtypes in very young women with breast cancer[J]. China Oncol, 2020, 30(10): 812-820. DOI: 10.19401/j.cnki.1007-3639.2020.10.013.
[25]
SHENG W Y, XIA S L, WANG Y R, et al. Invasive ductal breast cancer molecular subtype prediction by MRI radiomic and clinical features based on machine learning[J/OL]. Front Oncol, 2022, 12: 964605 [2023-05-05]. https://pubmed.ncbi.nlm.nih.gov/36172153/. DOI: 10.3389/fonc.2022.964605.
[26]
GUO J Z, LI C. Clinicopathological characteristics and prognosis analysis of different molecular typing of breast cancer[J]. J Med Theory Pract, 2017, 30(3): 421-423. DOI: 10.19381/j.issn.1001-7585.2017.03.065.
[27]
WANG L, PAN H F, LI Y. Analysis of staging and clinicopathological characteristics of different molecular subtypes with prognostic staging[J]. J Clin Surg, 2019, 27(3): 231-234. DOI: 10.3969/j.issn.1005-6483.2019.03.017.
[28]
OHYU S, TOZAKI M, SASAKI M, et al. Combined use of texture features and morphological classification based on dynamic contrast-enhanced MR imaging: differentiating benign and malignant breast masses with high negative predictive value[J]. Magn Reson Med Sci, 2022, 21(3): 485-498. DOI: 10.2463/mrms.mp.2020-0160.
[29]
DENG Y, YANG B R, LIU Z Q, et al. Three-dimensional texture analysis of contrast enhanced magnetic resonance imaging in the differential diagnosis of benign and malignant breast lesions[J]. Radiol Pract, 2019, 34(4): 436-439. DOI: 10.13609/j.cnki.1000-0313.2019.04.014.
[30]
XIA X D, DUAN C Z, WANG G X, et al. Prediction of axillary lymph node metastasis of breast cancer with MRI texture analysis[J]. Chin J Med Imag Technol, 2021, 37(4): 531-536. DOI: 10.13929/j.issn.1003-3289.2021.04.013.
[31]
WANG M, WANG X L, ZHANG J, et al. The value of identifying benign and malignant breast lesions based on the texture feature of Tirm sequence combined with time-intensity curve[J]. Chin J Magn Reson Imag, 2021, 12(6): 83-87. DOI: 10.12015/issn.1674-8034.2021.06.016.
[32]
DU T M, ZHAO H D. Texture analysis of enhanced MRI and pathological slides predicts EGFR mutation status in breast cancer[J/OL]. Biomed Res Int, 2022, 2022: 1376659 [2023-05-05]. https://pubmed.ncbi.nlm.nih.gov/35663041/. DOI: 10.1155/2022/1376659.
[33]
FAN X H, XIE N, CHEN J W, et al. Multiparametric MRI and machine learning based radiomic models for preoperative prediction of multiple biological characteristics in prostate cancer[J/OL]. Front Oncol, 2022, 12: 839621 [2023-05-05]. https://pubmed.ncbi.nlm.nih.gov/35198452/. DOI: 10.3389/fonc.2022.839621.
[34]
CHENG J, LIANG X, ZHENG S S, et al. Predictors of breast cancer screening utilization among female at high risk of developing breast cancer: application of a Lasso Logistic model[J]. Chin J Dis Contr Prev, 2018, 22(6): 551-554, 559. DOI: 10.16462/j.cnki.zhjbkz.2018.06.003.
[35]
MAYERHOEFER M E, MATERKA A, LANGS G, et al. Introduction to radiomics[J]. J Nucl Med, 2020, 61(4): 488-495. DOI: 10.2967/jnumed.118.222893.
[36]
XUE K, DING Y Y, SUN S Y, et al. Dynamic contrast-enhanced MR texture analysis for assessment of heterogeneity of different molecular subtypes of breast cancer[J]. J Med Imag, 2020, 30(2): 221-226.
[37]
HOLLI-HELENIUS K, SALMINEN A, RINTA-KIIKKA I, et al. MRI texture analysis in differentiating luminal A and luminal B breast cancer molecular subtypes-a feasibility study[J/OL]. BMC Med Imaging, 2017, 17(1): 69 [2023-05-05]. https://pubmed.ncbi.nlm.nih.gov/29284425/. DOI: 10.1186/s12880-017-0239-z.
[38]
XIE T W, ZHAO Q F, FU C X, et al. Differentiation of triple-negative breast cancer from other subtypes through whole-tumor histogram analysis on multiparametric MR imaging[J]. Eur Radiol, 2019, 29(5): 2535-2544. DOI: 10.1007/s00330-018-5804-5.
[39]
GRIMM L J, ZHANG J, MAZUROWSKI M A. Computational approach to radiogenomics of breast cancer: Luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms[J]. J Magn Reson Imaging, 2015, 42(4): 902-907. DOI: 10.1002/jmri.24879.
[40]
MA X W. Preliminary study on the prediction of breast cancer molecular typing based on the imaging features of breast DCE-MRI[D]. Shenyang: China Medical University, 2019. DOI: 10.27652/d.cnki.gzyku.2019.001109.
[41]
WU J, SUN X L, WANG J, et al. Identifying relations between imaging phenotypes and molecular subtypes of breast cancer: model discovery and external validation[J]. J Magn Reson Imaging, 2017, 46(4): 1017-1027. DOI: 10.1002/jmri.25661.

PREV Application of quantitative parameters based on T1 mapping sequence in identifying pathological types of lung cancer
NEXT Magnetic resonance imaging features and related factors of breast edema in idiopathic granulomatous mastitis
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn